Etao International Co., Ltd.
OOTC:ETAOF0.00
USD
0.00
(0.00%)
ISIN
KYG313631155
CUSIP
G31363115
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
-100.00
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Wen Sheng Liu
- Full Time Employees
- 3,600
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 1460 Broadway New York NY United States 10036
- IPO Date
- Jun 17, 2022
- Website
- etao.world
- Similar Companies
- Business
- ETAO International Co., Ltd. (ETAOF) operates as a digital healthcare company that develops an integrated ecosystem encompassing online telemedicine, artificial intelligence diagnostics, big data evaluation, online insurance, pharmacy services, biotechnology solutions, offline hospitals, and specialty clinics including infertility treatment, orthopedic surgery, plastic surgery, primary care, and digital diabetes management. The company, incorporated in 2020 and headquartered in New York, New York with operations across North America, China, Canada, Latin America, and Australia, maintains a network of 12 hospitals, 30 clinics, and digital platforms serving over 5 million registered users. ETAO International delivers AI-driven precision medicine, OMO (online-merge-offline) healthcare, and cross-border networks powered by technologies such as cloud pharmacy transactions, EMR analysis, online consultations, and AI cancer screening. Recent strategic acquisitions include HiPatho for digital pathology, DiaCarta for precision diagnostics, and 6D Dental for AI dental imaging, contributing to over 12 global healthcare capability enhancements and unaudited 2024 consolidated revenue exceeding $150 million USD with pro forma 2025 projections surpassing $660 million USD. In March 2024, the company executed a 1-for-20 reverse share split, increased authorized shares, and altered its share capital structure. ETAO International targets Nasdaq relisting by Q4 2025 following Q1-Q3 2025 milestones in legal planning, acquisition finalization, regulatory approvals, and operational integration, supported by internal cash reserves, PIPE funding, and strategic equity partners focused on dental, AI medical technology, and U.S. healthcare assets.